Delivering a realistic diabetes prevention programme in a UK community: the Norfolk Diabetes Prevention Study (Norfolk DPS)

orfolk and Norwich University Hospital NHS Trust (UK)0 sites1,330 target enrollmentApril 14, 2016

Overview

2017 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/28056894 protocol 2018 Results article in https://www.ncbi.nlm.nih.gov/pubmed/29674706 results (added 17/04/2019) 2019 Results article in https://www.ncbi.nlm.nih.gov/pubmed/31245004 results (added 03/02/2020) 2019 Results article in https://www.ncbi.nlm.nih.gov/pubmed/31420897 results (added 03/02/2020) 2021 Results article in https://pubmed.ncbi.nlm.nih.gov/33136119/ results (added 03/11/2020) 2021 Results article in https://pubmed.ncbi.nlm.nih.gov/34407811/ (added 19/05/2023)

Registry

who.int

Start Date

April 14, 2016

End Date

April 1, 2018

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

orfolk and Norwich University Hospital NHS Trust (UK)

•1\. Fasting plasma glucose 5\.6 \- 6\.0 mmol/l AND HbA1c 42 \- 47 inclusive on two occasions, OR fasting plasma glucose 6\.1 \- 6\.9 inclusive on two occasions, both categories for the diabetes prevention project
•2\. Fasting plasma glucose \> or \= to 7\.0 mmol/l on two occasions, OR HbA1c \> or \= to 48 mmol/mol on two occasions for the screen\-detected Type 2 diabetes project
•3\. These criteria are gender independent, but main search criteria for subjects through primary care databases is 40 \- 80 years old

•1\. Not able to provide GP details i.e. not registered with a GP or unwilling for their GP to be contacted
•2\. Unable to give informed consent due to lack of capacity through severe mental health, learning difficulties or significant cognitive impairment
•3\. Self\-reported conditions which could adversely affect the trial results or patient clinical well being such as:
•3\.1\. Terminal illness
•3\.2\. Antipsychotic medication, which may affect glucose tolerance
•3\.3\. High dose oral steroids (\> 4 weeks or \> 7\.5 mg)
•3\.4\. Active treatment for malignancy
•3\.5\. Stage IV renal impairment or ongoing renal dialysis
•3\.6\. Pregnant or lactating
•3\.7\. Stage IV NYHA cardiac failure